SSSuresh de Silva

Suresh de Silva

*This is an algorithmically generated author record based on publicly available information.

Suresh de Silva has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease

    by Mahmud Hussain, Anne Y Lai, Derek Franklin, Karen Lenz, Arpita Patel, Noah Murr, Harunobu Kato, Lini Pandite, Taylor H Schreiber, Suresh de Silva

    Background: Death receptor 3 (DR3; also termed tumor necrosis factor receptor superfamily member 25 [TNFRSF25]) is the sole functional receptor for tumor necrosis factor (TNF)–like cytokine 1A (TL1A) and is constitutively expressed on effector lymphoid cells in peripheral blood and in both inflamed and adjacent noninflamed tissues. Excessive DR3 signaling contributes to chronic inflammation in inflammatory bowel disease (IBD). While clinical trials of anti-TL1A antibodies have demonstrated efficacy in ulcerative colitis and Crohn disease, the stable expression pattern of DR3 suggests that receptor blockade may more effectively and durably inhibit TL1A-driven proinflammatory signaling and limit disease propagation. We describe the preclinical development of SL-325, a fully human, Fc-silent, high-affinity DR3-blocking monoclonal antibody. Methods: Binding affinity and specificity of SL-325 were evaluated using biophysical and cell-based assays. Functional activity was assessed in peripheral blood mononuclear cells (PBMCs) from healthy donors and IBD patients, an ex vivo human intestinal inflammation model, and cynomolgus macaque toxicology studies. Results: SL-325 bound to human DR3 with picomolar affinity and high specificity while potently blocking TL1A binding without inducing DR3 agonism. SL-325 suppressed TL1A-induced proinflammatory cytokine secretion in PBMCs from healthy donors and IBD patients. In an ex vivo human intestinal model, SL-325 inhibited TL1A-driven cytokine production and preserved epithelial barrier integrity. In nonhuman primates, SL-325 was safe and well tolerated at doses up to 100 mg/kg, demonstrated dose-proportional pharmacokinetics, and led to prolonged DR3 receptor occupancy (RO) without immune activation or proliferation. Conclusion: These data demonstrate that SL-325 is a novel DR3-blocking antibody with the potential to provide durable inhibition of the TL1A/DR3 axis and support the clinical development of SL-325 to treat IBD.


  • Open Access

    Figure S1 from Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses

    by Casey W. Shuptrine, Yuhui Chen, Jayalakshmi Miriyala, Karen Lenz, Danielle Moffett, Thuy-Ai Nguyen, Jenn Michaux, Kristen Campbell, Connor Smith, Marc Morra, et al.

    Figure S1 from Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses

  • Open Access

    Figure S1 from Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses

    by Casey W. Shuptrine, Yuhui Chen, Jayalakshmi Miriyala, Karen Lenz, Danielle Moffett, Thuy-Ai Nguyen, Jenn Michaux, Kristen Campbell, Connor Smith, Marc Morra, et al.

    Figure S1 from Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses

  • Open Access

    Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses

    by Casey W. Shuptrine, Yuhui Chen, Jayalakshmi Miriyala, Karen Lenz, Danielle Moffett, Thuy-Ai Nguyen, Jenn Michaux, Kristen Campbell, Connor Smith, Marc Morra, et al.

    Lipid nanoparticle (LNP)–encapsulated mRNA has been used for in vivo production of several secreted protein classes, such as IgG, and has enabled the development of personalized vaccines in oncology. Establishing the feasibility of delivering complex multispecific modalities that require higher-order structures important for their function could help expand the use of mRNA/LNP biologic formulations. Here, we evaluated whether in vivo administration of mRNA/LNP formulations of SIRPα-Fc-CD40L and TIGIT-Fc-LIGHT could achieve oligomerization and extend exposure, on-target activity, and antitumor responses comparable with that of the corresponding recombinant fusion proteins. Intravenous infusion of the formulated LNP-encapsulated mRNAs led to rapid and sustained production of functional hexameric proteins in vivo, which increased the overall exposure relative to the recombinant protein controls by ∼28 to 140 fold over 96 hours. High concentrations of the mRNA-encoded proteins were also observed in secondary lymphoid organs and within implanted tumors, with protein concentrations in tumors up to 134-fold greater than with the recombinant protein controls 24 hours after treatment. In addition, SIRPα-Fc-CD40L and TIGIT-Fc-LIGHT mRNAs induced a greater increase in antigen-specific CD8+ T cells in the tumors. These mRNA/LNP formulations were well tolerated and led to a rapid increase in serum and intratumoral IL2, delayed tumor growth, extended survival, and outperformed the activities of benchmark mAb controls. Furthermore, the mRNA/LNPs demonstrated improved efficacy in combination with anti-PD-L1 relative to the recombinant fusion proteins. These data support the delivery of complex oligomeric biologics as mRNA/LNP formulations, where high therapeutic expression and exposure could translate into improved patient outcomes. Significance: Lipid nanoparticle–encapsulated mRNA can efficiently encode complex fusion proteins encompassing immune checkpoint blockers and costimulators that functionally oligomerize in vivo with extended pharmacokinetics and durable exposure to induce potent antitumor immunity.


  • Analysis of Butyrophilin-Mediated Activation of γδ T Cells from Human Spleen

    by Chunyan Wang, Anne Y. Lai, Dana C. Baiu, Kelsey A Smith, Jon S. Odorico, Keith Wilson, Taylor Schreiber, Suresh de Silva, Jenny E Gumperz

    There is considerable interest in therapeutically engaging human γδ T cells. However, due to the unique TCRs of human γδ T cells, studies from animal models have provided limited directly applicable insights, and human γδ T cells from key immunological tissues remain poorly characterized. In this study, we investigated γδ T cells from human spleen tissue. Compared to blood, where Vδ2+Vγ9+ T cells are the dominant subset, splenic γδ T cells included a variety of TCR types, with Vδ1+ T cells typically being the most frequent. Intracellular cytokine staining revealed that IFN-γ was produced by a substantial fraction of splenic γδ T cells, IL-17A by a small fraction, and IL-4 was minimal. Primary splenic γδ T cells frequently expressed NKG2D (NK group 2 member D) and CD16, whereas expression of DNAM-1 (DNAX accessory molecule 1), CD28, PD-1, TIGIT, and CD94 varied according to subset, and there was generally little expression of natural cytotoxicity receptors, TIM-3, LAG-3, or killer Ig-like receptors. In vitro expansion was associated with marked changes in expression of these activating and inhibitory receptors. Analysis of functional responses of spleen-derived Vδ2+Vγ9+, Vδ1+Vγ9+, and Vδ1+Vγ9− T cell lines to recombinant butyrophilin BTN2A1 and BTN3A1 demonstrated that both Vδ2+Vγ9+ and Vδ1+Vγ9+ T cells were capable of responding to the extracellular domain of BTN2A1, whereas the addition of BTN3A1 only markedly enhanced the responses of Vδ2+Vγ9+ T cells. Conversely, Vδ1+Vγ9+ T cells appeared more responsive than Vδ2+Vγ9+ T cells to TCR-independent NKG2D stimulation. Thus, despite shared recognition of BTN2A1, differential effects of BTN3A1 and coreceptors may segregate target cell responses of Vδ2+Vγ9+ and Vδ1+Vγ9+ T cells.


  • Open Access

    Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists

    by George Fromm, Suresh de Silva, Taylor H. Schreiber

    The extracellular domain of tumor necrosis factor receptors (TNFR) generally require assembly into a homotrimeric quaternary structure as a prerequisite for initiation of signaling via the cytoplasmic domains. TNF receptor homotrimers are natively activated by similarly homo-trimerized TNF ligands, but can also be activated by synthetic agonists including engineered antibodies and Fc-ligand fusion proteins. A large body of literature from pre-clinical models supports the hypothesis that synthetic agonists targeting a diverse range of TNF receptors (including 4-1BB, CD40, OX40, GITR, DR5, TNFRSF25, HVEM, LTβR, CD27, and CD30) could amplify immune responses to provide clinical benefit in patients with infectious diseases or cancer. Unfortunately, however, the pre-clinical attributes of synthetic TNF receptor agonists have not translated well in human clinical studies, and have instead raised fundamental questions regarding the intrinsic biology of TNF receptors. Clinical observations of bell-shaped dose response curves have led some to hypothesize that TNF receptor overstimulation is possible and can lead to anergy and/or activation induced cell death of target cells. Safety issues including liver toxicity and cytokine release syndrome have also been observed in humans, raising questions as to whether those toxicities are driven by overstimulation of the targeted TNF receptor, a non-TNF receptor related attribute of the synthetic agonist, or both. Together, these clinical findings have limited the development of many TNF receptor agonists, and may have prevented generation of clinical data which reflects the full potential of TNF receptor agonism. A number of recent studies have provided structural insights into how different TNF receptor agonists bind and cluster TNF receptors, and these insights aid in deconvoluting the intrinsic biology of TNF receptors with the mechanistic underpinnings of synthetic TNF receptor agonist therapeutics.


  • Open Access

    Supplementary Data from CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity

    by Suresh de Silva, George Fromm, Casey W. Shuptrine, Kellsey Johannes, Arpita Patel, Kyung Jin Yoo, Kaiwen Huang, Taylor H. Schreiber

  • Open Access

    Supplementary Data from CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity

    by Suresh de Silva, George Fromm, Casey W. Shuptrine, Kellsey Johannes, Arpita Patel, Kyung Jin Yoo, Kaiwen Huang, Taylor H. Schreiber

    Supplementary Figures 1-6 and Supplementary Tables 1-3